Frequency and Determinants of Adherence to Oral Anticoagulants in Stroke Patients with Atrial Fibrillation in Clinical Practice

被引:24
作者
Polymeris, Alexandros A. [1 ,2 ]
Traenka, Christopher [1 ,2 ]
Hert, Lisa [1 ,2 ]
Seiffge, David J. [1 ,2 ]
Peters, Nils [1 ,2 ]
De Marchis, Gian Marco [1 ,2 ]
Bonati, Leo H. [1 ,2 ]
Lyrer, Philippe A. [1 ,2 ]
Engelter, Stefan T. [1 ,2 ,3 ,4 ]
机构
[1] Univ Basel Hosp, Stroke Ctr, Petersgraben 4, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Neurol, Petersgraben 4, CH-4031 Basel, Switzerland
[3] Univ Basel, Neurorehabil Unit, Basel, Switzerland
[4] Felix Platter Hosp, Univ Ctr Med Aging, Basel, Switzerland
关键词
Atrial fibrillation; Stroke; Non-vitamin K antagonist oral nticoagulants; Adherence; elf-report; Determinants; ACUTE VENOUS THROMBOEMBOLISM; MEDICATION ADHERENCE; ISCHEMIC-STROKE; 1ST YEAR; DABIGATRAN; PERSISTENCE; THERAPY; PREVENTION; NONADHERENCE; RIVAROXABAN;
D O I
10.1159/000450750
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) are beneficial in patients with stroke and atrial fibrillation (AF). However, little is known about frequency and determinants of adherence to NOACs/NKAs in clinical practice. Methods: This is a single-center explorative study from the Novel Oral Anticoagulants in Stroke Patients (NOACISP)-LONGTERM registry. We included consecutive AF-stroke patients treated with NOACs/NKAs and followed up for 3-24 months. Adherence was assessed at follow-up using structured interviews and quantified as the proportion of prescribed doses taken (PDT). Outcome measures were (i) full adherence, (ii)>= 95% adherence and (iii) >= 80% adherence (i.e., PDT 100/>= 95/>= 80%). To explore determinants of full adherence, we compared characteristics of fully and non-fully adherent patients. Results: A total of 218 of 251 (86.9%) patients (48% female, mean age 77.9 +/- .1 years, 78% NOACs; 22% VKAs) were eligible for analysis with a median follow-up of 12 months: fully adherent were 78.4% patients (NOACs 77.1%, VKAs 83.3%, p = 0.35), >= 95% adherent were 95.4% and >= 80% adherent were 97.2%. Fully adherent patients took more pills daily (median (interquartile range) 7 (5-10) vs. 6 (4-8), p = 0.039), had more often previous antithrombotic treatment (70.8 vs. 53.2%, p = 0.023), caregiver-assisted medication administration (54.2 vs. 19.1%, p < 0.001) and functional dependency (32.8 vs. 15%, p = 0.011) than non fully adherent patients. Conclusions: Full adherence was frequent. Patients naive to antithrombotics, taking few pills, which they self-administer, were at the highest risk of nonadherence and may benefit most from adherence-enhancing interventions. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:187 / 193
页数:7
相关论文
共 50 条
  • [41] Eligibility of patients with atrial fibrillation for new oral anticoagulants
    Moubarak, Ghassan
    Badenco, Nicolas
    Dreyfus, Julien
    Simion, Constantin
    Delos Paquet, Aurelie
    Cazeau, Serge
    Cador, Romain
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 165 (03) : 573 - 574
  • [42] Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation
    Forslund, Tomas
    Wettermark, Bjorn
    Hjemdahl, Paul
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (03) : 329 - 338
  • [43] Ischemic stroke in oral anticoagulated patients with atrial fibrillation
    D'Anna, Lucio
    Filippidis, Filippos T.
    Harvey, Kirsten
    Korompoki, Eleni
    Veltkamp, Roland
    ACTA NEUROLOGICA SCANDINAVICA, 2022, 145 (03): : 288 - 296
  • [44] The new oral anticoagulants in atrial fibrillation: an update
    F. W. A. Verheugt
    Netherlands Heart Journal, 2013, 21 : 480 - 484
  • [45] Real-world adherence to oral anticoagulants in atrial fibrillation
    Simonyi Gabor
    Paksy Andras
    Varnai Reka
    Medvegy Mihaly
    ORVOSI HETILAP, 2020, 161 (20) : 839 - 845
  • [46] Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea
    Lee, Myung-Yong
    Han, Sola
    Bang, Oh Young
    On, Young Keun
    Jang, Sung-Won
    Han, Seongwook
    Ryu, Jaeyun
    Park, Yoo-Jung
    Kang, Seongsik
    Suh, Hae Sun
    Kim, Young-Hoon
    ADVANCES IN THERAPY, 2022, 39 (07) : 3112 - 3130
  • [47] Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban
    Potpara, Tatjana S.
    Polovina, Marija M.
    Licina, Marina M.
    Stojanovic, Radan M.
    Prostran, Milica S.
    Lip, Gregory Y. H.
    ADVANCES IN THERAPY, 2012, 29 (06) : 491 - 507
  • [48] Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban
    Tatjana S. Potpara
    Marija M. Polovina
    Marina M. Licina
    Radan M. Stojanovic
    Milica S. Prostran
    Gregory Y. H. Lip
    Advances in Therapy, 2012, 29 : 491 - 507
  • [49] Longitudinal Oral Anticoagulant Adherence Trajectories in Patients With Atrial Fibrillation
    Salmasi, Shahrzad
    De Vera, Mary A.
    Safari, Abdollah
    Lynd, Larry D.
    Koehoorn, Mieke
    Barry, Arden R.
    Andrade, Jason G.
    Deyell, Marc W.
    Rush, Kathy
    Zhao, Yinshan
    Loewen, Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (24) : 2395 - 2404
  • [50] Novel oral anticoagulants in patients with atrial fibrillation, how to avoid accidents?
    Manenti, Vladimir
    Aliot, Etienne
    PRESSE MEDICALE, 2014, 43 (7-8): : 775 - 783